PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsInterferon beta-1b
Betaseron, Betaferon(interferon beta-1b)
Betaferon, Betaseron, Extavia (interferon beta-1b) is a protein pharmaceutical. Interferon beta-1b was first approved as Betaseron on 1993-07-23. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis.
Download report
Favorite
Novartis Pharmaceuticals
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
immune system diseasesD007154
Trade Name
FDA
EMA
Betaseron (discontinued: Extavia)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Interferon beta-1b
Tradename
Proper name
Company
Number
Date
Products
Betaseroninterferon beta-1bBayerN-103471 RX1993-07-23
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
betaseronBiologic Licensing Application2023-07-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple sclerosisEFO_0003885D009103G35
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AB: Interferons
— L03AB08: Interferon beta-1b
HCPCS
Code
Description
J1830
Injection, interferon beta-1b, 0.25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Clinical
Clinical Trials
99 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G35—5653752
SclerosisD012598———4643346
Relapsing-remitting multiple sclerosisD020529EFO_0003929——4241020
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic progressive multiple sclerosisD020528EFO_0003840———1—23
Hiv infectionsD015658EFO_0000764B20——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart diseasesD006331EFO_0003777I51.9—1———1
CardiomyopathiesD009202EFO_0000318I42—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FatigueD005221—R53.83————11
DepressionD003863—F33.9————11
AtrophyD001284——————11
Cognitive dysfunctionD060825—G31.84————11
Congenital abnormalitiesD000013EFO_0003915Q89.9————11
Pregnancy complicationsD011248——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameInterferon beta-1b
INN—
Description
Interferon beta precursor (IFN-beta) (Fibroblast interferon)
Classification
Protein
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201563
ChEBI ID—
PubChem CID—
DrugBankDB00068
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,111 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
31,973 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use